AONC (American Oncology Network) Piotroski F-Score: 0 (As of Jun. 25, 2026)


AONC American Oncology Network Inc AONC
20 GF Score
Price $10.00
View Full Analysis

What is American Oncology Network Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

American Oncology Network has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for American Oncology Network's Piotroski F-Score or its related term are showing as below:

American Oncology Network  (OTCPK:AONC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


American Oncology Network Piotroski F-Score Related Terms


American Oncology Network Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for American Oncology Network's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network Piotroski F-Score Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
N/A N/A N/A N/A 4.00

American Oncology Network Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A 4.00
AONC
20GF Score
American Oncology Network Inc AONC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -7.841 + 3.621 + -1.069 + 1.316 = $-4 Mil.
Cash Flow from Operations was 45.137 + -33.927 + -28.079 + 11.926 = $-5 Mil.
Revenue was 364.339 + 433.982 + 470.279 + 490.884 = $1,759 Mil.
Gross Profit was 9.391 + 29.393 + 36.533 + 42.529 = $118 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(374.453 + 421.921 + 430.762 + 394.811 + 470.328) / 5 = $418.455 Mil.
Total Assets at the begining of this year (Dec23) was $374 Mil.
Long-Term Debt & Capital Lease Obligation was $135 Mil.
Total Current Assets was $331 Mil.
Total Current Liabilities was $217 Mil.
Net Income was 0 + 0 + -1.792 + -3.75 = $-6 Mil.

Revenue was 303.731 + 314.967 + 336.305 + 324.182 = $1,279 Mil.
Gross Profit was 25.197 + 23.568 + 25.411 + 8.62 = $83 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(326.228 + 0 + 0 + 394.014 + 374.453) / 5 = $364.89833333 Mil.
Total Assets at the begining of last year (Dec22) was $326 Mil.
Long-Term Debt & Capital Lease Obligation was $120 Mil.
Total Current Assets was $278 Mil.
Total Current Liabilities was $169 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

American Oncology Network's current Net Income (TTM) was -4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

American Oncology Network's current Cash Flow from Operations (TTM) was -5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-3.973/374.453
=-0.01061014

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-5.542/326.228
=-0.01698812

American Oncology Network's return on assets of this year was -0.01061014. American Oncology Network's return on assets of last year was -0.01698812. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

American Oncology Network's current Net Income (TTM) was -4. American Oncology Network's current Cash Flow from Operations (TTM) was -5. ==> -5 <= -4 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=135.141/418.455
=0.32295229

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=120.444/364.89833333
=0.3300755

American Oncology Network's gearing of this year was 0.32295229. American Oncology Network's gearing of last year was 0.3300755. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=331.472/216.847
=1.5285985

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=277.803/169.045
=1.64336715

American Oncology Network's current ratio of this year was 1.5285985. American Oncology Network's current ratio of last year was 1.64336715. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

American Oncology Network's number of shares in issue this year was 41.343. American Oncology Network's number of shares in issue last year was 6.899. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=117.846/1759.484
=0.06697759

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=82.796/1279.185
=0.06472559

American Oncology Network's gross margin of this year was 0.06697759. American Oncology Network's gross margin of last year was 0.06472559. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=1759.484/374.453
=4.69881133

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=1279.185/326.228
=3.92113798

American Oncology Network's asset turnover of this year was 4.69881133. American Oncology Network's asset turnover of last year was 3.92113798. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

American Oncology Network has an F-score of 4 indicating the company's financial situation is typical for a stable company.


American Oncology Network Business Description

Address 14543 Global Parkway, Suite 110, Fort Myers, FL, USA, 33913
American Oncology Network Inc through its subsidiary companies and variable interest entities, is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 37 oncology practices located in twenty states. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging.
20GF Score

Get the complete analysis for AONC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price